# Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

> **NCT06792734** · PHASE1 · RECRUITING · sponsor: **Bantam Pharmaceuticals** · enrollment: 24 (estimated)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** BTM-3566

## Key facts

- **NCT ID:** NCT06792734
- **Lead sponsor:** Bantam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-14
- **Primary completion:** 2027-02
- **Final completion:** 2027-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06792734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06792734, "Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06792734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*